INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune in Patients with Metastatic Castration-Resistant Prostate Cancer

02.01.2024 - Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight  disease, dosed ... Seite 1

Related Keywords

Boca Raton ,Florida ,United States ,California ,Matt Rettig ,University Of California ,Jonsson Comprehensive Cancer Center ,Nasdaq ,David Geffen School Of Medicine ,Prostate Cancer Program ,Inmune Bio Inc ,Professor Matt Rettig ,Medical Director ,Geffen School ,Jonsson Comprehensive Cancer ,Professor Rettig ,Inmune Bio Chart ,Nmune Bio Kurs ,Inmune Bio Aktie ,